The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells

Biomaterials

Volumn 34, Issue 21, 2013, Pages 5138-5148

  Gu, Guangzhi ^a   Gao, Xiaoling ^b   Hu, Quanyin ^a   Kang, Ting ^a   Liu, Zhongyang ^a   Jiang, Mengyin ^c   Miao, Deyu ^c   Song, Qingxiang ^b   Yao, Lei ^b   Tu, Yifan ^a   Pang, Zhiqing ^a   Chen, Hongzhuan ^b   Jiang, Xinguo ^a   Chen, Jun ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Co administration; Glioblastoma; IRGD; MT1 AF7p; Nanoparticle; Paclitaxel

Indexed keywords

CO-ADMINISTRATION; GLIOBLASTOMAS; IRGD; MT1-AF7P; PACLITAXEL;

BINDING ENERGY; BLOOD VESSELS; CELL DEATH; DRUG DELIVERY; LOADING; MOLECULAR BIOLOGY; NANOPARTICLES; PEPTIDES;

TUMORS;

MACROGOL; MATRIX METALLOPROTEINASE 14; NANOPARTICLE; PACLITAXEL; POLYLACTIC ACID;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ENDOCYTOSIS; EXTRAVASATION; FEASIBILITY STUDY; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIPID RAFT; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PINOCYTOSIS; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT DURATION; TUMOR SPHEROID; ZETA POTENTIAL;

ANIMALS; BRAIN NEOPLASMS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL-PENETRATING PEPTIDES; COUMARINS; DIAGNOSTIC IMAGING; ENDOCYTOSIS; GLIOMA; MALE; MATRIX METALLOPROTEINASE 14; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; OLIGOPEPTIDES; PACLITAXEL; RATS; SPHEROIDS, CELLULAR; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION;

MUS MUSCULUS;

EID: 84877037947     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.036     Document Type: Article

References (50)

1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEngl J Med 2005, 352:987-996.
2. Nduom E.K., Bouras A., Kaluzova M., Hadjipanayis C.G. Nanotechnology applications for glioblastoma. Neurosurg Clin N Am 2012, 23:439-449.
3. Liu S., Guo Y., Huang R., Li J., Huang S., Kuang Y., et al. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials 2012, 33:4907-4916.
4. Agarwal S., Sane R., Oberoi R., Ohlfest J.R., Elmquist W.F. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 2011, 13:e17.
5. Lawson H.C., Sampath P., Bohan E., Park M.C., Hussain N., Olivi A., et al. Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. JNeurooncol 2007, 83:61-70.
6. Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., Batchelor T.T. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8:610-622.
7. Zhan C., Meng Q., Li Q., Feng L., Zhu J., Lu W. Cyclic RGD-polyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene delivery. Chem Asian J 2012, 7:91-96.
8. Xie H., Xue Y.X., Liu L.B., Liu Y.H. Endothelial-monocyte-activating polypeptide II increases blood-tumor barrier permeability by down-regulating the expression levels of tight junction associated proteins. Brain Res 2010, 1319:13-20.
9. Minchinton A.I., Tannock I.F. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592.
10. Grantab R., Sivananthan S., Tannock I.F. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 2006, 66:1033-1039.
11. Phillips R.M., Loadman P.M., Cronin B.P. Evaluation of a novel invitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer 1998, 77:2112-2119.
12. Rozhkova E.A. Nanoscale materials for tackling brain cancer: recent progress and outlook. Adv Mater 2011, 23:H136-H150.
13. Orringer D.A., Koo Y.E., Chen T., Kopelman R., Sagher O., Philbert M.A. Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. Clin Pharmacol Ther 2009, 85:531-534.
14. Beduneau A., Saulnier P., Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28:4947-4967.
15. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32:8010-8020.
16. Zhan C., Gu B., Xie C., Li J., Liu Y., Lu W. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. JControl Release 2010, 143:136-142.
17. Forsyth P.A., Wong H., Laing T.D., Rewcastle N.B., Morris D.G., Muzik H., et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999, 79:1828-1835.
18. Nakada M., Kita D., Futami K., Yamashita J., Fujimoto N., Sato H., et al. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma. JNeurosurg 2001, 94:464-473.
19. Deryugina E.I., Soroceanu L., Strongin A.Y. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res 2002, 62:580-588.
20. Munaut C., Noel A., Hougrand O., Foidart J.M., Boniver J., Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 2003, 106:848-855.
21. Belien A.T., Paganetti P.A., Schwab M.E. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. JCell Biol 1999, 144:373-384.
22. Fillmore H.L., VanMeter T.E., Broaddus W.C. Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. JNeurooncol 2001, 53:187-202.
23. Nakada M., Okada Y., Yamashita J. The role of matrix metalloproteinases in glioma invasion. Front Biosci 2003, 8:e261-e269.
24. Zhu L., Wang H., Wang L., Wang Y., Jiang K., Li C., et al. High-affinity peptide against MT1-MMP for invivo tumor imaging. JControl Release 2011, 150:248-255.
25. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. JControl Release 2012, 161:175-187.
26. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4:806-813.
27. Lee H., Fonge H., Hoang B., Reilly R.M., Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm 2010, 7:1195-1208.
28. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
29. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Greenwald D.R., et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328:1031-1035.
30. Bello L., Francolini M., Marthyn P., Zhang J., Carroll R.S., Nikas D.C., et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001, 49:380-389. 390.
31. Ding H., Wu X., Roncari L., Lau N., Shannon P., Nagy A., et al. Expression and regulation of neuropilin-1 in human astrocytomas. Int J Cancer 2000, 88:584-592.
32. Xia H., Gao X., Gu G., Liu Z., Zeng N., Hu Q., et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 2011, 32:9888-9898.
33. Gu G., Xia H., Hu Q., Liu Z., Jiang M., Kang T., et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials 2013, 34:196-208.
34. Zeng N., Gao X., Hu Q., Song Q., Xia H., Liu Z., et al. Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and invivo absorption. Int J Nanomedicine 2012, 7:3703-3718.
35. Hu Q., Gu G., Liu Z., Jiang M., Kang T., Miao D., et al. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery. Biomaterials 2013, 34:1135-1145.
36. Yu D.H., Lu Q., Xie J., Fang C., Chen H.Z. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010, 31:2278-2292.
37. Ulrich T.A., Jain A., Tanner K., MacKay J.L., Kumar S. Probing cellular mechanobiology in three-dimensional culture with collagen-agarose matrices. Biomaterials 2010, 31:1875-1884.
38. Jiang X., Xin H., Gu J., Xu X., Xia W., Chen S., et al. Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel. Biomaterials 2013, 34:1739-1746.
39. Allard E., Passirani C., Benoit J.P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009, 30:2302-2318.
40. Norden A.D., Drappatz J., Wen P.Y. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009, 5:610-620.
41. Hu K., Li J., Shen Y., Lu W., Gao X., Zhang Q., et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: invitro and invivo evaluations. JControl Release 2009, 134:55-61.
42. Pellet-Many C., Frankel P., Jia H., Zachary I. Neuropilins: structure, function and role in disease. Biochem J 2008, 411:211-226.
43. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
44. Song Q., Yao L., Huang M., Hu Q., Lu Q., Wu B., et al. Mechanisms of transcellular transport of wheat germ agglutinin-functionalized polymeric nanoparticles in Caco-2 cells. Biomaterials 2012, 33:6769-6782.
45. Xia H., Gao X., Gu G., Liu Z., Hu Q., Tu Y., et al. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int J Pharm 2012, 436:840-850.
46. Vercauteren D., Vandenbroucke R.E., Jones A.T., Rejman J., Demeester J., De Smedt S.C., et al. The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls. Mol Ther 2010, 18:561-569.
47. Nakase I., Niwa M., Takeuchi T., Sonomura K., Kawabata N., Koike Y., et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 2004, 10:1011-1022.
48. Mehta G., Hsiao A.Y., Ingram M., Luker G.D., Takayama S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. JControl Release 2012, 164:192-204.
49. Pampaloni F., Reynaud E.G., Stelzer E.H. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007, 8:839-845.
50. Xin H., Sha X., Jiang X., Zhang W., Chen L., Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 2012, 33:8167-8176.